Results · Apr-Jun 2026
Nectar Lifesciences Q1 FY27 results
Sales fell 100% to ₹0.01 crore from ₹281 crore in Apr-Jun 2025.
Operating profit was −₹27.7 crore, an operating margin of −191031.0% (down 191009.0 points from a year ago).
The net loss narrowed to ₹15.7 crore from ₹63.2 crore.
Against Jan-Mar 2026: loss narrows.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 0.0 | 280.7 | −100% |
| Operating profit (EBITDA) | -27.7 | -61.9 | n/m |
| Operating margin | −191031.0% | −22.1% | −191009.0 pts |
| Net profit | -15.7 | -63.2 | loss narrows |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.